Pedaling for health: a study evaluating how energy-generating exercise bikes can improve cardiovascular health

Double-blind randomized clinical trial protocol: evaluating the impact of energy-generating ergometer bicycles on cardiovascular health

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

REBEC

Registry ID

RBR-62vn8h2

Enrollment

Registered

2026-06-07

Start date

2026-09-15

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial pressure

Interventions

This is a three-arm, parallel, double-blind randomized controlled clinical trial. A total of 96 participants will be included, with 32 individuals allocated to each group. There will be two Interventi

Eligibility

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Body Mass Index (BMI) between 25 and 35 kg/m²; No prior history of diagnosed cardiovascular disease; Male; Female; Age 18 until 60.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Verify systolic and diastolic blood pressure (mmHg), measured at rest with a calibrated sphygmomanometer; resting heart rate (bpm), recorded after 10 minutes of rest; total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides (mg/dL), assessed in venous blood samples after a 12-hour fast, with LDL calculated using the Friedewald formula (when triglycerides < 400 mg/dL) or measured directly; fasting blood glucose (mg/dL), also obtained by laboratory testing of venous blood after a 12-hour fast; waist circumference (cm), measured with a non-stretchable measuring tape at the midpoint between the iliac crest and the last rib; and VO2 max (mL/kg/min), estimated through a submaximal test on a cycle ergometer or treadmill, using a validated protocol. It is expected that the intervention groups will show improvements in clinical outcomes compared to the control group, with better indicators observed in the intervention group that generates energy.	—

Measure

Time frame

Verify systolic and diastolic blood pressure (mmHg), measured at rest with a calibrated sphygmomanometer; resting heart rate (bpm), recorded after 10 minutes of rest; total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides (mg/dL), assessed in venous blood samples after a 12-hour fast, with LDL calculated using the Friedewald formula (when triglycerides < 400 mg/dL) or measured directly; fasting blood glucose (mg/dL), also obtained by laboratory testing of venous blood after a 12-hour fast; waist circumference (cm), measured with a non-stretchable measuring tape at the midpoint between the iliac crest and the last rib; and VO2 max (mL/kg/min), estimated through a submaximal test on a cycle ergometer or treadmill, using a validated protocol. It is expected that the intervention groups will show improvements in clinical outcomes compared to the control group, with better indicators observed in the intervention group that generates energy.

—

Secondary

Measure	Time frame
No secondary outcomes are expected	—

Countries

Contacts

Public ContactMonica Carvalho

Universidade Federal da Paraíba

monica@cear.ufpb.br+55 (83) 32167268

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Jun 29, 2026